BRIGHT MINDS BIOSCIENCES INC (DRUG) — insider trading
Health Care · NASDAQ
BRIGHT MINDS BIOSCIENCES INC (DRUG) has 13 reported SEC Form 4 insider transactions in our data, including 12 open-market purchases and 1 open-market sale among the most recent 13 (latest 2026-04-28).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-28 | Cormorant Asset Management, LP; Chen Bihua; Cormorant Global Healthcare Master Fund, LP | Other | Open-market sale | 109,331 | $89.50 | $9.79M | Form 4 |
| 2024-11-04 | Cormorant Asset Management, LP; Chen Bihua | 10% owner | Open-market purchase | 184,331 | $21.70 | $4.00M | Form 4 |
| 2024-10-16 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 3,107 | $25.22 | $78.4K | Form 4 |
| 2024-10-16 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 7,150 | $24.03 | $171.8K | Form 4 |
| 2024-10-16 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 39,743 | $23.22 | $922.6K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 4,609 | $12.35 | $56.9K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 19,169 | $11.72 | $224.6K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 2,700 | $9.26 | $25.0K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 2,600 | $8.80 | $22.9K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 8,900 | $7.31 | $65.0K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 33,343 | $6.42 | $214.2K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 63,173 | $5.92 | $374.2K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua | 10% owner | Open-market purchase | 238,097 | $4.53 | $1.08M | Form 4 |
Ask the chat about DRUG's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BRIGHT MINDS BIOSCIENCES INC (DRUG).
Last updated 2026-04-28 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.